Chemoprevention of Head and Neck Cancer

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2003 Feb 14

PMID 12583833

Citations 1

Authors

Katrina Y Glover

Vali A Papadimitrakopoulou

Affiliations

Soon will be listed here.

Abstract

Squamous cell carcinoma of the head and neck is the most common epithelial neoplasm of the upper aerodigestive tract and represents a major health concern in the United States and worldwide. Invasive squamous cell carcinoma is the end result of a multiyear, multistep process of accumulation of genetic and phenotypic damage. Chemoprevention is defined as the use of pharmacologic or natural agents that inhibit the development of invasive cancer whether by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Chemoprevention is widely recognized as an important area of research in head and neck cancer. This article reviews the field of chemoprevention and recent advances in molecular epidemiology and genetics. Current clinical trials are described.

Citing Articles

PPARγ in head and neck cancer prevention.

Burotto M, Szabo E Oral Oncol. 2014; 50(10):924-9.

PMID: 24434068 PMC: 4096621. DOI: 10.1016/j.oraloncology.2013.12.020.

References

Shin D, Ro J, Hong W, Hittelman W . Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994; 54(12):3153-9. View

Partridge M, Pateromichelakis S, Phillips E, Emilion G, AHern R, Langdon J . A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 2000; 60(14):3893-8. View

Lippman S, BATSAKIS J, Toth B, Weber R, Lee J, Martin J . Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993; 328(1):15-20. DOI: 10.1056/NEJM199301073280103. View

Hong W, Lippman S, Itri L, Karp D, Lee J, Byers R . Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990; 323(12):795-801. DOI: 10.1056/NEJM199009203231205. View

Saracci R . The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev. 1987; 9:175-93. DOI: 10.1093/oxfordjournals.epirev.a036301. View

Yang C, Wang Z . Tea and cancer. J Natl Cancer Inst. 1993; 85(13):1038-49. DOI: 10.1093/jnci/85.13.1038. View

Sanchez-Cespedes M, Esteller M, Wu L, Yoo G, Koch W, Jen J . Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000; 60(4):892-5. View

Cooper J, Pajak T, Rubin P, Tupchong L, BRADY L, Leibel S . Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989; 17(3):449-56. DOI: 10.1016/0360-3016(89)90094-1. View

Kennedy A, Manzone H . Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. J Cell Biochem Suppl. 1995; 22:188-94. DOI: 10.1002/jcb.240590824. View

10.

Jemal A, Thomas A, Murray T, Thun M . Cancer statistics, 2002. CA Cancer J Clin. 2002; 52(1):23-47. DOI: 10.3322/canjclin.52.1.23. View

11.

Han J, Jiao L, Lu Y, Sun Z, Gu Q, Scanlon K . Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo. 1990; 4(3):153-60. View

12.

Shields P, Harris C . Molecular epidemiology and the genetics of environmental cancer. JAMA. 1991; 266(5):681-7. View

13.

Shin D, Khuri F, Murphy B, Garden A, Clayman G, Francisco M . Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001; 19(12):3010-7. DOI: 10.1200/JCO.2001.19.12.3010. View

14.

Agarwal R, Mukhtar H . Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol. 1996; 401:35-50. DOI: 10.1007/978-1-4613-0399-2_4. View

15.

De Stefani E, Correa P, Oreggia F, Leiva J, Rivero S, Fernandez G . Risk factors for laryngeal cancer. Cancer. 1987; 60(12):3087-91. DOI: 10.1002/1097-0142(19871215)60:12<3087::aid-cncr2820601238>3.0.co;2-6. View

16.

Rubin Grandis J, Tweardy D, Melhem M . Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998; 4(1):13-20. View

17.

Panje W . Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol. 1981; 107(11):658-63. DOI: 10.1001/archotol.1981.00790470006003. View

18.

van der Riet P, Nawroz H, Hruban R, Corio R, Tokino K, Koch W . Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 1994; 54(5):1156-8. View

19.

TUYNS A, Esteve J, Raymond L, Berrino F, Benhamou E, Blanchet F . Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer. 1988; 41(4):483-91. DOI: 10.1002/ijc.2910410403. View

20.

Guo Z, Yamaguchi K, Sanchez-Cespedes M, Westra W, Koch W, Sidransky D . Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res. 2001; 7(7):1963-8. View